Thermo Fisher Scientific Inc. (TMO)
Thermo Fisher wins contracts as pharma shifts production to US, CEO says
Thermo Fisher Scientific's pharmaceutical services business has won a number of contracts to help its customers move production from Europe or Asia to the U.S., the medical equipment maker's CEO, Marc Casper, said on Tuesday.
The Lab Equipment Titan Trading at Half the Multiple Just Delivered Another Beat
Danaher (NYSE: DHR) and Thermo Fisher Scientific (NYSE: TMO) both reported Q3 2025 earnings showing revenue growth around 5%, but underlying business momentum tells very different stories.
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
TMO Stock May Benefit From PPD CorEvitas Alzheimer's Registry Launch
Thermo Fisher launches a global PPD CorEvitas Alzheimer's registry, enrolling its first patient to generate real-world safety and effectiveness data.
TMO Stock Set to Gain From the Expansion of Gibco Bacto Portfolio
Thermo Fisher expands its Gibco Bacto CD portfolio with new formulations aimed at boosting E. coli-based plasmid DNA and protein production efficiency.
TMO Stock Benefits From New Bioprocess Design Center in Asia
Thermo Fisher expands its Bioprocess Design Centers across Asia, boosting biomanufacturing speed, efficiency and regional innovation.
Why Is Thermo Fisher (TMO) Up 0.2% Since Last Earnings Report?
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?
TMO Stock May Rise Post New PCR Test in Collab With Coca-Cola Partner
Thermo Fisher's new all-in-one SureTect qPCR assay promises faster, broader beverage spoilage detection and sharper quality control.
These 3 Stocks Are Using Buybacks to Signal Market Confidence
Several key stocks are making notable buyback announcements. Below, we examine the latest moves by Trade Desk, Thermo Fisher, and Tapestry—and what they reveal about each company's capital return strategy.
Thermo Fisher Scientific to acquire Clario in $8.9B cash deal
Thermo Fisher Scientific Inc (NYSE:TMO, ETR:TN8) announced on Wednesday that it has agreed to acquire Clario Holdings Inc, a provider of endpoint data solutions for clinical trials, for $8.875 billion in cash plus potential performance-driven payouts. Thermo Fisher is purchasing the company from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven.
Thermo Fisher to buy clinical services provider Clario for up to $9.4 billion
Thermo Fisher said on Wednesday it would buy privately held data management company Clario for up to $9.4 billion, strengthening its clinical trial research business amid a strong rebound in demand in the U.S.
Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 Billion
Thermo Fisher Scientific agreed to acquire endpoint data solutions provider Clario Holdings from a shareholder group for $8.88 billion in cash.
